D. Pluim

W. Dreschler, M. Hauptmann, J. Schellens, 2021, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

J. Schellens, H. Rosing, J. Beijnen, 2016, British journal of clinical pharmacology.

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

J. Schellens, J. Beijnen, P. Baas, 2015, Investigational New Drugs.

Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines

J. Schellens, J. Beijnen, D. Pluim, 2004, Cancer Chemotherapy and Pharmacology.

Platinated DNA Adducts Enhance Poisoning of DNA Topoisomerase I by Camptothecin*

J. Schellens, M. Bjornsti, D. Pluim, 2004, Journal of Biological Chemistry.

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2

Jos H. Beijnen, Alfred H. Schinkel, J. Schellens, 2007, Molecular Cancer Therapeutics.

Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA

J. Schellens, J. Beijnen, D. Pluim, 2013, Investigational New Drugs.

Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases

J. Schellens, J. Beijnen, K. Sikorska, 2020, Neurology.

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

D. de Jong, J. Schellens, J. Beijnen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors

J. Schellens, J. Beijnen, S. Howell, 2004, Clinical Cancer Research.

Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin

J. Schellens, H. Rosing, J. Beijnen, 2008, Analytical and bioanalytical chemistry.

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours

J. Beijnen, A. Howes, W. S. Siegel-Lakhai, 2005, British Journal of Cancer.

Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei

J. Schellens, D. Pluim, J. Thomale, 2006, Nucleic acids research.

“Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183”

J. Schellens, J. Beijnen, D. Pluim, 2014, Investigational New Drugs.

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

F H Hausheer, J. Schellens, J. Beijnen, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models

Jos H. Beijnen, Piet Borst, Gerrit Jansen, 2007, Molecular Pharmacology.

Abcc 4 together with Abcb 1 and Abcg 2 form a robust co-operative drug efflux system that restricts the brain entry of camptothecin analogs

J. Beijnen, D. Pluim, R. Mazzanti, 2013 .

The N‐terminus of amine oxidase of Hansenula polymorpha contains a peroxisomal targeting signal

K. Faber, D. Pluim, M. Veenhuis, 1995, FEBS letters.

Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer

J. Schellens, M. Verheij, D. Pluim, 2020, Clinical Cancer Research.

Phase I pharmacological study of continuous chronomodulated capecitabine treatment

J. Schellens, H. Rosing, J. Beijnen, 2020, Pharmaceutical Research.

Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma

J. Schellens, M. Egorin, D. Pluim, 2004, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin

J. Schellens, J. Beijnen, G. Groenewegen, 2002, Cancer Chemotherapy and Pharmacology.

Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor

H. Bartelink, F. Hoebers, L. Stalpers, 2007, Cancer Chemotherapy and Pharmacology.

Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors

J. Schellens, H. Rosing, J. Beijnen, 2009, Clinical Cancer Research.

EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors.

J. Westerga, J. Schellens, J. Beijnen, 2016, Neuro-oncology.

EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid

J. Schellens, J. Beijnen, D. Pluim, 2018, Journal of Neuro-Oncology.

New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine

Jos H. Beijnen, Jashvant D. Unadkat, J. Schellens, 2008, Molecular Cancer Therapeutics.

Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials.

Conchita Vens, Heike Peulen, J. Schellens, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first‐line treatment of patients with advanced HER2‐negative gastric cancer: A multicenter phase 2 study

J. Schellens, J. Beijnen, K. Sikorska, 2016, Cancer.

Increased risk of severe fluoropyrimidine‐associated toxicity in patients carrying a G to C substitution in the first 28‐bp tandem repeat of the thymidylate synthase 2R allele

J. Schellens, J. Beijnen, D. Pluim, 2016, International journal of cancer.

Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination

J. Schellens, J. Beijnen, D. Pluim, 2013, Analytical and Bioanalytical Chemistry.

A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine

Jos H. Beijnen, J. Schellens, H. Rosing, 2016, Cancer Chemotherapy and Pharmacology.

Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular‐signal‐regulated kinase and DNA in circulating tumor cells

J. Schellens, J. Beijnen, D. Pluim, 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

J. Beijnen, J. Schellens, D. Pluim, 1999, Analytical biochemistry.

WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.

J. Beijnen, M. V. van Vugt, A. Huitema, 2023, Gynecologic oncology.

In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM.

J. Schellens, D. Pluim, M. de Graaff, 1999, Anti-cancer drugs.

Phase I pharmacological study of continuous chronomodulated capecitabine treatment

J. Schellens, H. Rosing, J. Beijnen, 2018, Pharmaceutical Research.

Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (<3 months) to standard first line therapy.

D. Jong, J. Schellens, J. Beijnen, 2015 .

New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine

J. Schellens, J. Beijnen, D. Pluim, 2008, Molecular Cancer Therapeutics.

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam

H. Rosing, D. Pluim, A. Bergman, 2023, Journal of clinical pharmacology.